Insecticides (India) Limited reported a 24% year-on-year decline in consolidated net profit after tax (PAT) to ₹44 crore for the first quarter of FY27, ending June 30, 2026. The contraction was primarily driven by a 12% drop in revenue from operations to ₹612 crore from ₹691 crore in Q1FY26, which management attributed to rainfall deficits across India. Despite the top-line pressure, the company maintained gross profit stability at ₹193 crore, expanding its gross profit margin by 240 basis points to 31.6% from 29.2% through disciplined pricing actions. The Board of Directors approved the unaudited financial results in its meeting held on August 11, 2026, and the results were subsequently published in newspapers including Business Standard on August 12, 2026, pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

The earnings release highlighted that while gross margins improved, operating leverage eroded as expenses rose. Consolidated EBITDA fell 20% to ₹68 crore from ₹85 crore in the prior year period, compressing the EBITDA margin to 11.1% from 12.2%. Profit before tax declined to ₹58.82 crore, impacted by higher finance costs and depreciation charges, leading to the significant drop in bottom-line profitability. The standalone PAT for the quarter stood at ₹41.83 crore, down from ₹57.30 crore in Q1FY26.

Financial Performance Overview

The following table details the consolidated financial results for Q1FY27 compared to the previous year:

Profit after tax settled at ₹44 crore, down from ₹58 crore in Q1FY26. The company’s total turnover for FY26 stood at ₹2,140 crore, providing context for the quarterly performance against the full-year baseline. Basic earnings per share (EPS) for the consolidated entity declined to ₹15.08 from ₹19.97 in the corresponding period last year.

Strategic Initiatives and Product Launches

Despite near-term headwinds, Insecticides India advanced several strategic initiatives during the quarter. The company executed a pan-India mega launch of GRANUVIA, a next-generation insecticide developed in collaboration with Corteva Agriscience. This was supported by extensive engagement with distributors, dealers, and farmers. Additionally, Spinoace was introduced as part of this collaboration.

The company’s KAEROS brand continued its strong trajectory, expanding its portfolio and distribution footprint while reinforcing its position as a strategic growth lever. Management plans to double the number of ILL Crop Solutions (ICS plots) from the current 36, covering four major crops—rice, cotton, chilli, and soybean—across 14 states. High-impact farmer outreach efforts included over 3,600 farmer meetings, 600 field days, 1,400 demonstrations, and more than 15,000 farmer visits in Q1FY27.

What the Numbers Show

A key divergence in the Q1FY27 results is the resilience of gross margins against declining revenue. Rajesh Kumar Aggarwal, Managing Director, stated that pricing discipline and operating efficiencies helped maintain stability in gross margins despite deficient rainfall impacting demand. The expansion in gross margin suggests effective premiumization strategies, likely supported by the Focus Maharatna and Maharatna portfolios. However, the inability to pass these efficiencies to the EBITDA level indicates rising operational costs or fixed cost burdens that are not yet being offset by volume growth. The company remains focused on backward integration and capacity expansion to build a more resilient organization for future quarters.

Insecticides (India) Limited reported a significant decline in profitability for the quarter ended June 30, 2026, with standalone net profit falling 27% year-on-year to ₹4,183.05 million. The downturn was mirrored in consolidated figures, where net profit attributable to owners dropped 24% to ₹4,387.44 million, signaling pressure across the group's agro-chemical operations due to lower sales volumes and margin compression.

The Board of Directors approved the unaudited financial results on August 11, 2026, following a review by the Audit Committee. The results were subjected to a limited review by joint statutory auditors S S Kothari Mehta & Co., LLP and Devesh Parekh & Co., in accordance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Financial Performance Overview

Revenue from operations declined for both standalone and consolidated entities compared to the same period in FY25. Standalone revenue fell 11% to ₹61,648.22 million from ₹69,137.24 million, while consolidated revenue dropped similarly to ₹61,152.31 million from ₹69,113.31 million. This top-line contraction directly impacted bottom-line results, despite relatively stable cost structures.

Operating profitability also weakened during the quarter. Standalone EBITDA declined to ₹659 million from ₹840 million in the same period last year. The EBITDA margin contracted to 10.90% from 12.15% year-on-year, reflecting the combined impact of lower revenues and a relatively less flexible cost base during the period.

What the Numbers Show

The divergence between revenue decline and profit contraction highlights margin compression. While cost of materials consumed remained relatively flat at ₹38,641.98 million standalone versus ₹38,763.70 million last year, the reduction in revenue volume meant fixed costs like employee benefits (₹4,498.34 million vs ₹4,105.82 million) and other expenses (₹7,638.91 million vs ₹7,507.92 million) weighed more heavily on margins. This suggests operational inefficiencies or inability to pass on cost pressures during a period of reduced demand.

Additionally, the company continues its structural cleanup, having received approval for the dissolution of its wholly owned subsidiary IIL Overseas DMCC, Dubai, on September 19, 2025. This move aims to streamline operations, though its financial impact remains minimal in the current quarter.